Connect Biopharma Holdings Nasdaq/NYSE Compliance Notice
Connect Biopharma received a deficiency notice from Nasdaq on November 12, 2026, because its ordinary shares closed below the $1.00 minimum bid price requirement for 30 consecutive business days. The company has until May 11, 2027, to regain compliance by maintaining a closing bid price of at least $1.00 for at least ten consecutive business days. The notice has no immediate effect on the listing of the company's shares, which continue to trade under the symbol 'CNTB'.
- Counterparty
- Nasdaq
- Term
- 180 days
“We believe topline results from our Phase 2 Seabreeze STAT asthma and COPD studies mark a significant inflection point in the development of rademikibart as an add-on treatment to rescue bronchodilators and systemic corticosteroids for the treatment of acute exacerbations.”
Barry Quart, Pharm.D., CEO and Director of Connect Biopharma
“We believe these findings support the potential of rademikibart to redefine how acute exacerbations are managed, addressing both the acute event and the 4-week high-risk period following an exacerbation, to improve patient outcomes and reduce the substantial economic burden on healthcare systems.”
Barry Quart, Pharm.D., CEO and Director of Connect Biopharma